Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SSTR3 | P32745 | 20/20 | 0.58 |
| ▸ | KCNH2 | Q12809 | 15/20 | 0.58 |
| ▸ | SSTR1 | P30872 | 1/20 | 0.45 |
| ▸ | SSTR2 | P30874 | 1/20 | 0.45 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.45 |
| ▸ | SSTR5 | P35346 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12377723 | 0.97 | SSTR3 (0.60) | SSTR3KCNH2SSTR1SSTR2SSTR4 | |
| SCHEMBL12377722 | 0.96 | SSTR3 (0.63) | SSTR3KCNH2SSTR1SSTR2SSTR4 | |
| SCHEMBL12377721 | 0.91 | SSTR3 (0.53) | SSTR3KCNH2SSTR1SSTR2SSTR4 | |
| SCHEMBL12377729 | 0.91 | SSTR3 (0.53) | SSTR3KCNH2SSTR1SSTR2SSTR4 | |
| SCHEMBL12377728 | 0.90 | SSTR3 (0.54) | SSTR3KCNH2SSTR1SSTR2SSTR4 | |
| SCHEMBL12377724 | 0.88 | SSTR3 (0.61) | SSTR3KCNH2SSTR1SSTR2SSTR4 | |
| SCHEMBL12377725 | 0.83 | SSTR3 (0.46) | SSTR3KCNH2SSTR1SSTR2SSTR4 | |
| SCHEMBL12377668 | 0.83 | SSTR3 (0.44) | SSTR3KCNH2SSTR1SSTR2SSTR4 | |
| SCHEMBL12377666 | 0.81 | SSTR3 (0.65) | SSTR3KCNH2SSTR1SSTR2SSTR4 | |
| SCHEMBL12377716 | 0.76 | SSTR3 (0.78) | SSTR3KCNH2SSTR1SSTR2SSTR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110201615-A1 | TRIAZOLE BETA CARBOLINE DERIVATIVES AS ANTI-DIABETIC AGENTS | MERCK SHARP & DOHME CORP. | 2011-08-18 | — | — | US | disclosed |
| US-20110201615-A1 | TRIAZOLE BETA CARBOLINE DERIVATIVES AS ANTI-DIABETIC AGENTS | MERCK SHARP & DOHME CORP. | 2011-08-18 | — | — | US | disclosed |
| WO-2010051177-A1 | TRIAZOLE BETA CARBOLINE DERIVATIVES AS ANTIDIABETIC COMPOUNDS | MERCK SHARP & DOHME CORP. (US) | 2010-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110201615-A1 | TRIAZOLE BETA CARBOLINE DERIVATIVES AS ANTI-DIABETIC AGENTS | GPR119, SSTR3, SSTR2 | SSTR3 2/4885KCNH2 953/4885SSTR1 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.